皮肤自发荧光、动脉僵硬度和Framingham风险评分对CKD患者临床结局的预测:一项队列研究
该队列研究纳入261例CKD 5期患者,评估SAF、AIx与FRS的关联及其对CVD死亡和全因死亡的预测价值。中位随访25个月,46例死亡。调整FRS后SAF与全因死亡相关,AIx与CVD死亡和全因死亡相关;进一步调整hsCRP、白蛋白和CVD后,AIx仍独立预测CVD死亡(HR 2.14)和全因死亡(HR 1.74)。
要点
- AIx在调整炎症、营养和CVD后仍独立预测CVD死亡和全因死亡。
- SAF与全因死亡相关,但调整混杂因素后独立性消失。
- ROC曲线中FRS+AIx对CVD死亡预测AUC达0.78,优于单一指标。
核心结论
- 在CKD 5期患者中,SAF和AIx与死亡相关且独立于FRS,但进一步调整后仅AIx保持独立预测作用。
研究设计与样本
- 前瞻性队列研究,纳入261例临床稳定的CKD 5期患者(中位年龄56岁,66%男性,20%糖尿病;130例非透析、93例腹膜透析、38例血液透析)。
主要发现
- 多因素回归中SAF与FRS、血红蛋白、脂肪BMI和CVD相关,与握力百分比负相关。
- ROC分析CVD死亡AUC从0.72(AIx和FRS分别)到0.78(FRS+AIx),全因死亡AUC从0.70(AIx)到0.79(FRS+AIx)。
- 调整FRS后,SAF每增加1-SD与全因死亡相关,AIx每增加1-SD与CVD死亡和全因死亡相关。
- 进一步调整hsCRP、白蛋白和CVD后,AIx仍独立预测CVD死亡(HR 2.14,95%CI 1.18-3.89)和全因死亡(HR 1.74,95%CI 1.16-2.60)。
关键数值与推荐
- CVD死亡AUC:AIx=0.72,FRS=0.72,FRS+AIx=0.78;全因死亡AUC:AIx=0.70,FRS+AIx=0.79。
- AIx预测CVD死亡HR 2.14(95%CI 1.18-3.89),全因死亡HR 1.74(95%CI 1.16-2.60)。
临床怎么用
- 在CKD 5期患者中,AIx可作为独立于传统风险因素和炎症的死亡风险分层指标。
- SAF的预测价值在调整混杂因素后减弱,提示传统CVD风险因素仍重要。
局限性
- SAF和AIx相比FRS在ROC曲线分析中的贡献相对有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The risk of cardiovascular disease (CVD) is predicted by Framingham's CVD risk scores (FRS) but the high CVD-related mortality in patients with chronic kidney disease (CKD) is only partially explained by traditional CVD risk markers. Therefore, there is a need to explore whether other CVD risk markers may improve risk prediction. Although arterial stiffness measured by augmentation index (AIx) and tissue content of advanced glycation end-products (AGEs) measured by skin autofluorescence (SAF) are two biomarkers that associate with CVD and mortality in CKD, it is not known how they compare with FRS. We evaluated associations between SAF, AIx and FRS, and their associations with CVD and mortality in CKD patients. METHODS: SAF (AGE Reader) and AIx (SphygmoCor; adjusted for 75 heart beats per minute) were measured in 261 clinically stable and extensively phenotyped patients with CKD Stage 5 (median age 56 years, 66% male, 20% diabetes; 130 non-dialysed, 93 patients on peritoneal dialysis and 38 patients on haemodialysis). Multivariate receiver operator characteristics (ROC) curve analysis and multivariate Cox models followed by C-statistics were used to evaluate CVD-related and all-cause mortality risk associated with SAF, AIx and FRS during follow-up for median 25 months with 46 deaths. RESULTS: In multivariate regression analysis, SAF associated with FRS, haemoglobin, fat body mass index and CVD, and inversely with per cent handgrip strength (HGS). AIx associated with FRS, and inversely with per cent HGS. Associations of SAF and AIx with high-sensitivity C-reactive protein (hsCRP), serum albumin, statin therapy and renal replacement therapy were not statistically significant. In ROC analysis, area under the curve (AUC) for CVD mortality ranged from AUC = 0.72 (AIx and FRS, respectively) to AUC = 0.78 (FRS + AIx), and for all-cause mortality from AUC = 0.70 (AIx) to AUC = 0.79 (FRS + AIx). In multivariate Cox analysis, after adjusting for 1-standard deviation (1-SD) of FRS, 1-SD increase of SAF associated with all-cause mortality and 1-SD increase of AIx associated with CVD mortality and all-cause mortality. After further adjustments for hsCRP, albumin and presence of CVD, AIx (but not SAF) remained independently associated with CVD mortality, hazard ratio (HR) 2.14 [95% confidence interval (95% CI) 1.18-3.89] and all-cause mortality, HR 1.74 (95% CI 1.16-2.60). CONCLUSIONS: In patients with CKD Stage 5, SAF and aortic stiffness associated with mortality, independently of FRS. After adjusting for additional confounders including inflammation, aortic stiffness remained as an independent predictor of outcome. Since the contribution of SAF and aortic stiffness compared with FRS in ROC curve analysis was relatively modest, this underlines the importance of traditional CVD risk factors in CKD.
引用
- Mukai H, Svedberg O, Lindholm B, et al. Skin autofluorescence, arterial stiffness and Framingham risk score as predictors of clinical outcome in chronic kidney disease patients: a cohort study. Nephrol Dial Transplant. 2019. PMID: 29378035. doi:10.1093/ndt/gfx371
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。